

Noninvasive ventilation in acute heart failure: use of continuous positive airway pressure in the emergency department

JOSÉ MANUEL CARRATALA¹, JOSEP MASIP²

¹Servicio de Urgencias-Unidad de Corta Estancia (UCE). Hospital General Universitario de Alicante, Spain.

²Servicio de Medicina Intensiva. Hospital Dos de Maig. Consorci Sanitari Integral. Universidad de Barcelona, Spain.

CORRESPONDENCE:

Dr. José Manuel Carratala Perales
Servicio de Urgencias/UCE
Hospital General Universitario
de Alicante
Pintor Baeza, 12
03010 Alicante, Spain
E-mail: batbueno@hotmail.com

RECEIVED:

30-4-2009

ACCEPTED:

28-5-2009

CONFLICT OF INTEREST:

None

Noninvasive ventilation is one of the ventilatory support systems available for treating the patient with acute respiratory failure. Orotracheal intubation is not required. The main modalities are continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP). Both alleviate respiratory distress quickly and have proven useful for treating acute heart failure due to acute pulmonary edema or pulmonary hypertension. The need for intubation and mortality are reduced. More experience has accumulated with CPAP, which is easier to manage and is associated with few complications. BiPAP, which is more complicated and requires more staff training, has been shown to improve respiratory failure more quickly in patients with heart failure and to be more effective in patients with hypercapnia or respiratory muscle fatigue. In spite of these benefits, noninvasive ventilation is little used in hospital emergency departments, probably because of the lack of staff training and commitment, low availability of material resources, and the absence of clear protocols, which ought to be available in all hospitals. This review aims to describe the role that noninvasive ventilation plays in improving oxygen saturation in the treatment of acute heart failure due to acute pulmonary edema or pulmonary hypertension and to define an appropriate protocol for using these modalities. [Emergencias 2010;22:49-55]

Key words: Acute heart failure. Noninvasive ventilation. Emergency health services.

Introduction

Acute heart failure (AHF) with acute lung edema (ALE) or associated with a hypertensive crisis is a common cause of acute respiratory failure (ARF) in the hospital emergency department (ED). Its incidence and impact are increasing, and sometimes reaches truly epidemic proportions¹.

In recent decades, non-invasive ventilation (NIV) with positive pressure has been widely used to treat both hypoxemic ARF and hypoxemia-hypercapnia frequently seen in patients with AHF². NIV does not require orotracheal intubation (OTI) or sedation and has proved useful in the treatment of various forms of ARF³.

For the treatment of AHF, two modes of NIV have proved effective: continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP). Both modes, together with pharmacological treatment for AHF (diuretics, vasodilators,

inotropic agents, morphine), have been shown to improve early clinical and blood gas parameters, reducing the number of IOT and its complications, intensive care unit (ICU) admissions and hospital mortality in certain patients, as compared with traditional methods of oxygenation⁴.

There is greater experience with CPAP for the treatment of ARF associated with AHF, but the BiPAP mode is recommended when there is evidence of hypercapnia ($\text{PaCO}_2 > 50$ mmHg) and respiratory acidosis ($\text{pH} < 7.25$)⁵⁻⁷.

However, despite these benefits, the use of NIV in the ED is not widespread and only used in less than 6% of patients with AHF⁸. This may be due to lack of training in the technique and the absence of guidelines and protocols. This review aims to establish the role of NIV as a method of oxygenation in the treatment of AHF due to hypertensive ALE and to define an action protocol that facilitates the use of NIV in the ED.

Modes of non-invasive ventilation in ALE

CPAP

This is the most common mode of oxygenation used in the treatment of AHF with ALE and / or hypertensive crisis. It is simple to manage, with low costs and few complications⁹.

It involves continuous positive pressure in the airway and consists of a spontaneous ventilation mode that can optionally be applied without the aid of a fan¹⁰. It is not exactly a mechanical system of ventilation, and is better defined as a mode of continuous positive pressure oxygenation of the airway.

The application of continuous positive pressure air causes deployment or recruitment of partially or completely collapsed alveolar units, improves lung compliance, increases transpulmonary pressure and functional residual capacity. This enhances the effort of breathing and gas exchange¹¹. At the hemodynamic level, CPAP results in decreased preload and afterload (by reducing venous return and systolic tension of the left ventricular wall) with a slight decrease in systolic blood pressure and cardiac output in patients with normal cardiac function. In heart failure patients with increased pulmonary capillary pressure and fluid overload, it can increase cardiac output¹².

The comparison of CPAP with traditional oxygenation systems⁴ shows a significant declining rate of intubation (between 50-60%) and of hospital mortality (40-47%), and is considered the oxygen therapy system of choice for the early treatment of AHF associated with ALE⁴. It is recommended as Class IIa with level of evidence A in the guidelines for the diagnosis and treatment of AHF by the European Society of Cardiology¹³ and the recommendations of the British Thoracic Society (BTS) for the treatment of hypoxemic ARF due to ALE¹⁴.

BiPAP

This also consists of applying continuous air pressure, but helps the patient during inspiration by means of a ventilator. The result is ventilation with two pressure levels, one inspiratory (IPAP) and other expiratory (EPAP)¹⁵.

When BiPAP is compared against conventional oxygen therapy, it shows significantly reduced OTI (50%) and mortality (40%)^{4,16,17}. On comparing CPAP and BiPAP, no significant differences appear in the proportion of intubations, short-term mor-

tality or hospital stay, but BiPAP shows faster improvement of clinical and blood gas parameters, especially in the presence of hypercapnia and respiratory acidosis¹⁸⁻²⁰.

Since the CPAP technique is simpler, requires minimal training, little experience and less expensive equipment, it is recommended as initial treatment of AHF with ALE¹⁴. The use of BiPAP is indicated when CPAP fails, or when there is an initial association with hypercapnia and respiratory acidosis²¹.

Types of ventilators, interfaces and non-mechanical devices in NIV

Types of ventilators

NIV can be achieved using conventional ventilators (less effective) or those specifically designed for this ventilatory function (less sophisticated but high performance)²².

Traditionally, ventilators are described as being of limited volume (ventilation of the chronically ill) or limited pressure (recommended in acute illness). Ventilators of limited pressure designed for NIV are portable, manageable, and cost effective. In these devices, a turbine originates the flow, taking in ambient air to generate inspiratory and expiratory pressures (IPAP and EPAP). These ventilators can cycle by flow or pressure. They usually have a sensor to detect flow variations, responding rapidly to inspiratory and expiratory cycles. Patient inspiratory flow triggers the release of IPAP and flow reduction leads to exhalation where expiratory pressure is maintained constantly positive, or EPAP²¹. The circuit is simple in bidirectional ventilators (such as BiPAP Vision® or BiPAP Focus®) with an anti-reinhalation valve at the distal end and a pressure valve (sensor) attached to ventilator and to the interface²³.

Not all ventilators can regulate FIO₂ (fraction of oxygen in inspired air) which is an essential parameter in ventilation. When no other source of auxiliary oxygen is available, direct input from an external source to the interface is necessary.

Interfaces

The interface or mask is what makes this type of ventilation non-invasive. Correct choice is fundamental for the success of NIV, and requires a balance between minimizing leakage and maximising patient comfort. The most frequently used NIV masks for acute patients are oro-nasal and to-

tal facial masks. Nasal masks are usually used in chronic respiratory disease²⁴. The helmet has also been used successfully, but is usually limited to treating respiratory failure with acute CPAP or as an alternative in the case of skin complications in patients with prolonged ventilation²⁵. Helmet use has been questioned in the treatment of acute hypercapnia because cycling is more difficult and may favour CO₂ re-inspiration. Helmet price, less availability and less emergency staff experience mean it is a less common interface. It is also important to have various devices for securing the masks.

Non-mechanical CPAP devices

In addition to CPAP incorporated into mechanical ventilators, there are two non-mechanical continuous flow systems capable of generating continuous positive airway pressure throughout the respiratory cycle: a system connected to an airtight mask with an interchangeable exhalation valve (PEEP), and a system with a virtual PEEP valve as part of the mask (Boussignac system). In Boussignac CPAP a virtual PEEP valve is generated inside a small open tube due to turbulent flow resulting from the confluence of four high-flow jets inside. Pressure level is regulated by a flowmeter and controlled with a manometer or using tables. It has a FIO₂ ring regulator and a T-shaped nebulizer. Handling is simple and requires little training, with low cost and high performance²⁶.

Orotracheal intubation in ALE

The main benefit of NIV is avoidance of OTI. Thus, knowing OTI risk factors in patients with ALE can help as a guide for the indication of NIV. These criteria are shown in Table 1. Patients with these factors should automatically be candidates for NIV even though it may fail in many of them. However, since NIV has been shown to improve ARF more rapidly than conventional oxygen therapy, it can be used with most ALE patients, assuming adequate material and experience.

Factors associated with successful NIV in ALE

There are a number of factors that portend a good response to NIV (Table 2).

The experience and training of health professionals and cooperation or tolerance of the pa-

Table 1. Independent risk factors for intubation in acute cardiogenic lung edema

- Acute myocardial infarction with severely depressed left ventricular ejection fraction.
- APACHE II score > 21.
- Refractory hypercapnia.
- PH < 7.20.
- Systolic blood pressure < 140 mm Hg.
- High comorbidity (Charlson index > 3).
- Radiological pattern of extensive alveolar edema.

APACHE: acute physiologic and chronic health evaluation: pH < 7.20 is an independent parameter of maximum risk.

tient are important factors. Despite all these, NIV failure is possible, and most often reported in the elderly, the critical (high APACHE II or SAPS II scores) with non-hypercapnic ARF or with acute respiratory distress (ARDS) or pneumonia. It is also likely to fail when there is no improvement of hypoxemia after 30-60 minutes^{27,28}.

NIV protocol in cardiogenic ALE

The evidence supports the benefits of NIV over conventional methods of oxygenation in the treatment of ALE and it should be considered as the first line of intervention. The existence of a protocol means increased degree of compliance and commitment by emergency medicine professionals^{29,30}. In our opinion, CPAP should be the method of choice for ALE treatment, given its simplicity, easy application and low cost.

General measures

Patient selection criteria

Clinical diagnosis and early implementation are critical for the success of the technique.

NIV should be applied along with the rest of the conventional measures and there are no contraindications for use, in the following forms of AHF:

Table 2. Factors associated with the success of noninvasive ventilation

- Patient-ventilator synchrony.
- Glasgow coma score over 9.
- Acceptance of the technique by the patient.
- Few secretions.
- No pneumonia.
- APACHE II score less than 21.
- Hypercapnia.
- Initial pH above 7.1.
- Good response in the first hour of treatment.
- Arterial hypertension at baseline.
- Good response to treatment, correction of acidosis and hypoxemia.

APACHE: acute physiologic and chronic health evaluation.

– ALE: sudden onset of dyspnea with accessory muscle use, $\text{SaO}_2 < 90\%$, respiratory rate > 30 rpm and compatible chest radiograph.

– Acute hypertensive heart failure: signs and symptoms of AHF accompanied by high systolic blood pressure, relatively preserved left ventricular systolic function and chest radiography compatible with ALE.

There should be no delay in starting NIV while waiting for the results of a chest radiograph or arterial blood gas test. The patient must be aware and co-operative at the start, hemodynamically stable, and able to maintain his/her airway and manage secretions.

Contraindications

There is no clear consensus on absolute and relative contraindications for the use of NIV³¹. Some are accepted as such on being described as exclusion criteria in many studies (Table 3).

Monitoring

The first 30-60 minutes are crucial for success of the technique. Therefore clinical control at the bedside is essential from the first moment. Heart rate, respiratory rate, SaO_2 and blood pressure must be monitored continuously and arterial or venous blood gas must be monitored intermittently³².

Initiation of NIV

1. Patient monitored.
2. Bed at 45 degrees.
3. Administer oxygen conventionally while setting up all the NIV instruments, prepare the harness attachment, select the type and size of the interface (the oronasal, total facial or helmet for ALE) and FIO_2 should be kept as high as possible.
4. Explain the technique to the patient, and that a "jet of air" will be felt, etc.).
5. Place some protection on the nasal bridge (colloid dressing, vaseline gauze) when using the oronasal mask.

6. Hold the mask to the patient's face (or offer it to the patient), without pressure, allowing the patient to adapt, and start ventilation, but not secured with the harness, without concern about leakage at this stage.

7. If systolic blood pressure on ED admission (independent risk factor for morbidity and mortality in AHF) is between 90-110 mmHg, inotropics are necessary to achieve higher values and initiate NIV.

CPAP

8. Select minimum pressure levels (5 cmH_2O manometer) and after 2-5 minutes of adaptation, increase by steps of 2 cmH_2O pressure until the value that yields best respiratory frequency, reducing respiratory effort and maintaining $\text{SpO}_2 > 90\%$. Values will range between 7-12 $\text{cm H}_2\text{O}$ (the pressure most frequently used is 10 $\text{cm H}_2\text{O}$)³³, with higher values if necessary (values above 20 $\text{cm H}_2\text{O}$ pose a risk of intolerance to the technique), with an FIO_2 as high as possible (ideally 100%).

9. Monitor the pressure and the degree of leakage (with a manometer if using devices that are not of the mechanical Boussignac CPAP type; needle oscillation should not exceed 1 $\text{cm H}_2\text{O}$).

10. Fasten the harness without undue tension, verify leakage, and apply more tension if required (In NIV, any harness allowing a 2 finger gap without difficulty is recommended, otherwise there may be excessive stress and risk of intolerance).

11. If bronchodilators are required, use a device designed to spray (T tube), without changing or interrupting CPAP oxygenation, connecting it to medicinal air rotamers at a pressure of 4-5 $\text{cm H}_2\text{O}$ ³⁴.

BIPAP

12. In patients with severe debut or signs of poor response to initial treatment, with hypercapnia and respiratory acidosis ($\text{pH} < 7.25$), BIPAP ventilation or noninvasive pressure support is an alternative to CPAP.

13. The approach is identical, starting with low IPAP (8-10 $\text{cm H}_2\text{O}$) and EPAP values (4 $\text{cm H}_2\text{O}$), to progress after adaptation to IPAP values between 12-20 $\text{cm H}_2\text{O}$ and EPAP of 5-6 $\text{cm H}_2\text{O}$, with maximum FIO_2 (if possible 100%) to achieve $\text{SaO}_2 > 90\%$ and obtain an average tidal volume approximately 7.10 ml x weight of the patient (volume higher than 400 ml for an adult weighing 70-80 Kg)³⁵. In patients with some degree of drowsiness, program the safety respiratory rate around 10-15 breaths per minute.

Table 3. Contraindications for noninvasive ventilation

- Inability to maintain airway: patient in coma not hypercapnic, or agitated.
- Recent gastrointestinal or upper airway surgery (<15 days), uncontrolled vomiting, active HDA.
- Inability to control secretions.
- Hemodynamic instability (established shock uncontrolled by fluids and / or vasoactive drugs), uncontrolled malignant arrhythmia.
- Epilepsy.
- Impossibility of securing the mask.
- Lack of training in the technique.

Table 4. Most common complications of noninvasive ventilation

- Discomfort.
- Injuries to the nasal bridge: erythema, ulceration.
- Claustrophobia.
- Dry mucous membranes or eye irritation.
- Gastric distension (common but tolerated).
- Low blood pressure.
- Intolerance of the technique: asynchrony.

Complications

NIV failure varies among different series, between one 7-42% of patients, but only 10-15% are due to technical complications, usually poor application of the technique (Table 4).

When to withdraw CPAP?

Withdrawal is usually progressive. In our experience the average time on CPAP in the ED is 3 hours. In general, CPAP can be withdrawn under the following conditions:

- Improvement of dyspnea, without use of ancillary muscles
- Heart rate < 100 bpm.
- Respiratory rate < 30 rpm.
- When, with FIO₂ of 50% (Venturi mask type) and spontaneous breathing (without CPAP), one achieves SaO₂ > 90% in a comfortable patient, with improved blood gas (PaO₂ > 70 mmHg or PaO₂/FIO₂ ratio > 200 mmHg).

Controversies in NIV

Risk of myocardial infarction and VNI

There has been controversy over the risk of acute myocardial infarction (AMI) when BIPAP is used in patients with ALE, especially after the publication of two papers that showed higher rates of AMI associated with this technique. The first study compared with CPAP and BIPAP, the second BIPAP versus high doses of nitrates. In the first, the average pressure support used was 5 cm H₂O (IPAP of 9 and EPAP of 4 cm H₂O) which is insufficient and probably caused hypoventilation with increased risk of myocardial ischemia. In the second, there was a patient selection bias with a greater proportion of patients with chest pain on admission treated with BIPAP and thus a higher probability that the AMI was the cause of ALE and not the result of treatment^{38,39}.

This theoretically higher incidence of AMI theory associated with BIPAP has not been confirmed in subsequent studies. Even a recent study performed specifically to quantify the risk of AMI in the ALE treated with NIV (CPAP compared with BIPAP) concluded that both modes are equally ef-

fective and have similar rates of AMI, but should be used with caution in patients with severely depressed ejection fraction^{40,41}.

Hypotension and NIV

This is rare with proper patient selection. The increase in intrathoracic pressure causes decreased venous return, which favors the onset of hypotension, and is clinically relevant in patients with low intravascular volume and / or severely depressed systolic function. The development of auto-PEEP, typical of chronic obstructive pulmonary disease (COPD), also favors the development of hypotension. Therefore NIV is not recommend in patients with low cardiac output or shock⁴².

Conclusions

Patients with ARF due to ALE generally benefit from the use of NIV (CPAP and BIPAP). Early use reduces the number of intubations and complications, enhances clinical and blood gas parameters, and hospital survival rates.

The benefits of CPAP over BIPAP are easy application, minimal staff training, adaptability to different treatment and low cost. CPAP by non-mechanical systems (Boussignac) offers maximum applicability. Thus NIV, especially CPAP, should be made available in all hospital and out-of-hospital emergency departments; training and the commitment of healthcare professionals is essential for implementation of this technique.

References

- 1 Markku S, Nieminen MS, Veli-Pekka H. Definition and epidemiology of acute heart failure syndromes. *Am J Cardiol*. 2005;96(supl):5G-10G.
- 2 Lieschimg T, Kwok H, Hill NS. Acute applications of non-invasive positive pressure ventilation. *Chest*. 2003;124:669-713.
- 3 Barreiro TJ, Gemmel DJ. Noninvasive ventilation. *Crit Care Clin*. 2007;23:201-22.
- 4 Masip J, Roque M, Sánchez B, Fernández R, Subirana M, Expósito JA. Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema-Systematic Review and Meta-analysis. *JAMA*. 2005;294:3124-30.
- 5 Nava S, Carbone G, Dibattista N. Noninvasive ventilation in cardiogenic pulmonary edema. *Am J Respir Crit Care Med*. 2003;168:1432-7.
- 6 Bellone A, Barbieri A, Bursi F, Vettorello M. Management of acute pulmonary edema in the emergency department. *Curr Heart Fail Rep*. 2006;3:129-35.
- 7 Masip J, Páez J, Betbese AJ, Vecilla F. Noninvasive ventilation for pulmonary edema in emergency room. *Am J Respir Crit Care Med*. 2004;169:1072-3.
- 8 Llorens P, Martín FJ, González-Armengol JJ, Herrero P, Jacob J, Álvarez AB, et al. Perfil clínico de los pacientes con Insuficiencia Cardíaca en los Servicios de Urgencias: Datos preliminares del estudio EAHFE (Epidemiology Acute Heart Failure Emergency). *Emergencias* 2008;20:154-63.
- 9 Moritz F, Benichou J, Vanhese M, Richard JC, Line S, Hellot MF, et al. Boussignac continuous positive airway pressure device in the emergency care of acute cardiogenic pulmonary oedema: a randomized pilot study. *Eur J Emerg Med*. 2003;10:204-8.
- 10 Masip J. Ventilación mecánica no invasiva en el edema agudo de pulmón. *Rev Esp Cardiol*. 2001;54:1023-8.

- 11 L'Her E, Taille S, Deye N, Lellouche F, Fraticelli A, Demoule A, et al. Physiological response of hypoxemic patients to different modes of noninvasive ventilation [abstract]. *Am J Respir Crit Care Med*. 2003;168:27.
- 12 Chadda K, Annane D, Hart N. Cardiac and respiratory effects of continuous positive airway pressure and noninvasive ventilation in acute cardiac pulmonary edema. *Crit Care Med*. 2002;30:2457-61.
- 13 Nieminen MS, Bohm M, Cowie MR. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. *Eur Heart J*. 2005;26:384-416.
- 14 British Thoracic Society Standards of Care Committee Non-invasive ventilation in acute respiratory failure Thorax. 2002;57:192-211.
- 15 Masip J. Non-Invasive ventilation. *Heart Fail Rev*. 2007;12:119-24.
- 16 Peter JV, Mora JL, Hughes JP, Graham P. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. *Lancet*. 2006;367:1155-63.
- 17 Masip J, Betbese AJ, Páez J, Vecilla F, Cañizares R, Padró J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary edema: a randomized study. *Lancet*. 2000;356:2126-32.
- 18 Bellone A, Vettorello M, Monari A, Cortellaro F, Coen D. Noninvasive pressure support ventilation vs. continuous positive airway pressure in acute hypercapnic pulmonary edema. *Intensive Care Med*. 2005;31:807-11.
- 19 Park M, Sangean MC, Volpe M de S, Feltrim MI, Nozawa E, Leite PF, et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. *Crit Care Med*. 2004;32:2407-15.
- 20 Cross AM, Cameron P, Kierce M, Ragg M, Kelly AM. Non-invasive ventilation in acute respiratory failure: a randomised comparison of continuous positive airway pressure and bi-level positive airway pressure. *Emerg Med J*. 2003;20:531-4.
- 21 Hess DR. The evidence for non-invasive positive-pressure ventilation in the care of patients in acute respiratory failure: A systematic review of the literature. *Respiratory Care* 2004;49:810-29.
- 22 Brochard L, Maggiore S. Noninvasive ventilation: Modes of ventilation. *Eur Respir Mon*. 2001;16:67-5.
- 23 Agawal R, Agarwal AN, Guota D. Non-invasive ventilation in acute cardiogenic pulmonary oedema. *Postgrad Med J*. 2005;81:637-43.
- 24 Kwok H, McCormack J, Cece R, Houtchens J, Hill NS. Controlled trial of oronasal versus nasal mask ventilation in the treatment of acute respiratory failure. *Crit Care Med*. 2003;31:468-73.
- 25 Tonnelier JM, Part G, Nowak E, Goetghebeur D, Renault A, Boles JM, et al. Noninvasive continuous positive pressure using a new helmet interface: A case prospective pilot study. *Intensive Care Med*. 2003;29:2077-80.
- 26 Esquinas A, Gómez ML. Modos Ventilatorios. *Tratado de Ventilación Mecánica No Invasiva. Práctica Clínica y Metodología*. 2006;153:1149-51.
- 27 Masip J, Paez J, Merino M, Parejo S, Vecilla F, Riera C, et al. Risk factors for intubation as a guide for noninvasive ventilation in patients with severe acute cardiogenic pulmonary edema. *Intensive Care Med*. 2003;29:1921-8.
- 28 Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. *Intensive Care Med*. 2001;27:1718-28.
- 29 Browning J, Atwood B, Gray A. Use of non-invasive ventilation in UK emergency departments. *Emerg Med J*. 2006;23:920-1.
- 30 Maheshwari V, Paioli D, Rothaar R, Hill NS. Utilization of noninvasive ventilation in acute care hospitals: a regional survey. *Chest*. 2006;129:1226-33.
- 31 Brochard L, Mancebo L, Elliott MW. Noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2002;19:712-21.
- 32 Mehta S, Hill NS. Noninvasive Ventilation. *Am J Crit Care Med*. 2001;163:540-77.
- 33 Kwok M Ho, Wong K. A comparison of continuous and bi-level positive airway pressure non-invasive ventilation in patients with acute cardiogenic pulmonary oedema: a meta-analysis. *Crit Care*. 2006;10:R49.
- 34 Carratalá JM, Albert AR, Murcia JM, Laghzaoui F, Fernández Cañadas JM, Llorens P. Terapia inhalada y ventilación no invasiva en modo CPAP. *Uso de CPAP de Boussignac. Cuidados Respiratorios y Tecnologías Aplicadas*. 2007;2:49-53.
- 35 Cabriada V, Camino J, Temprano M, Fernández A, Shenguelia L, Aretxederreta J. La VMNI en la EPOC reagudizada. *Manual práctico de ventilación no invasiva en medicina de urgencias y emergencias*. Madrid: Aula Médica; 2007.
- 36 Hill NS. Complications of noninvasive positive pressure ventilation. *Respir Care*. 1997;42:432-2.
- 37 Esquinas A, Gonzales Díaz G. Aspectos metodológicos. *Tratado de ventilación mecánica no invasiva. Práctica clínica y metodología*. Madrid: Aula Médica; 2006.
- 38 Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. *J Am Coll Cardiol*. 2000;36:832-7.
- 39 Mehta S, Jay GD, Woolard RH, Hipona RA, Connolly EM, Cimini DM, et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. *Crit Care Med*. 1997;25:620-8.
- 40 Bellone A, Monari A, Cortellaro F, Vettorello M, Arlati S, Coen D. Myocardial infarction rate in acute pulmonary edema: Noninvasive pressure support ventilation vs continuous positive airway pressure. *Crit Care Med*. 2004;32:1860-5.
- 41 Winck JC, Azevedo LF, Costa-Pereira A, Antonelli M, Wyatt JC. Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema – a systematic review and meta-analysis. *Crit Care*. 2006;10:R69.
- 42 Chawla R, Khilnani GC, Suri JC, Ramakrishnan N, Mani RK, Prayang S, et al. Guideline for non-invasive ventilation in acute respiratory failure. *Indian J Crit Care Med*. 2006;10:117-47.

Ventilación no invasiva en la insuficiencia cardiaca aguda: uso de CPAP en los servicios de urgencias

Carratala JM, Masip J

La ventilación no invasiva (VNI) es uno de los soportes ventilatorios que se ofrece al paciente con insuficiencia respiratoria aguda (IRA) y que no precisa intubación orotraqueal. Los modos usados con más frecuencia en la IRA son la presión positiva continua en la vía aérea (CPAP) y la ventilación con doble nivel de presión (BIPAP). Ambas modalidades han demostrado su utilidad en el tratamiento de la insuficiencia cardiaca aguda (ICA) por edema agudo de pulmón (EAP) o hipertensiva, al mejorar con mayor rapidez la IRA y reducir las necesidades de intubación y la mortalidad en algunos pacientes. Existe una mayor experiencia en el modo CPAP, más sencillo en su manejo y con pocas complicaciones, que con el modo BIPAP, más complejo y que requiere un mayor entrenamiento. Cuando se comparan ambos métodos en pacientes con ICA el modo BIPAP sólo ha demostrado mejorar la IRA con mayor rapidez y es más efectivo en pacientes con hipercapnia o fatiga respiratoria. A pesar de estos beneficios, el uso de la VNI en los servicios de urgencias hospitalarios está poco extendido probablemente debido a la falta de entrenamiento e implicación de los profesionales, la baja disponibilidad de recursos materiales y a la ausencia de protocolos claros, que deberían estar disponibles en todos los hospitales. La presente revisión pretende establecer el papel de la VNI como método de oxigenación en el tratamiento de la ICA por EAP e hipertensiva y definir un protocolo de actuación que facilite su cumplimiento. [Emergencias 2010;22:49-55]

Palabras clave: Insuficiencia cardiaca aguda. Ventilación no invasiva. Servicios de urgencias.